Global HIV Prevention Research and Development Investment Trends
Explore the comprehensive data on Global HIV Prevention Research and Development (R&D) investments from 2009 to 2013. The analysis covers funding sources, R&D categories, and changes in investment patterns over the years, providing valuable insights into the landscape of HIV prevention efforts.
Download Presentation
Please find below an Image/Link to download the presentation.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author. If you encounter any issues during the download, it is possible that the publisher has removed the file from their server.
You are allowed to download the files provided on this website for personal or commercial use, subject to the condition that they are used lawfully. All files are the property of their respective owners.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author.
E N D
Presentation Transcript
HIV Prevention Research & Development Investment in 2013 In a changing global development, economic, and human rights landscape Emily Donaldson, AVAC Presenting on behalf of the HIV Vaccines & Microbicides Resource Tracking Working Group Presented at the International AIDS & Economics Network Pre-conference, Melbourne, July 2014
Methodology Comprehensive and consistent investment data collection and disaggregation methodology since 2004 Data collection January June 2014 R&D Categories: Preventive HIV vaccines (307 grants) Microbicides (84 grants) Pre-exposure prophylaxis (54 grants) Treatment as prevention (80 grants) Male circumcision (20 grants) Female condom (4 grants) Prevention of vertical transmission (24 grants) HSV-2 vaccines (22 grants) HIV cure (150 grants) Therapeutic HIV vaccines (45 grants) Data Sources: Public funders (447 grants) Philanthropic (141 grants) Industry (7 grants) HIV Vaccines & Microbicides Resource Tracking Working Group
Global HIV Prevention R&D Investment, 2009 2013 (US$ millions) US$1.31B US$1.27B US$1.28B US$1.26B US$1.22B $1,200 $1,000 $800 $600 $400 $200 $0 2009 Female Condoms Treatment as Prevention* Pre-exposure Prophylaxis Preventive Vaccines 2010 2011 2012 2013 Prevention of Vertical Transmission Adult Male Circumcision Microbicides HIV Vaccines & Microbicides Resource Tracking Working Group
Global HIV Prevention R&D Investment 2013 by Funder Type (US$ millions) 37, 3% 193, 15% 65, 5% 77, 6% 887, 71% US Public-Sector Other Governments Industry European Public-Sector Philanthropic HIV Vaccines & Microbicides Resource Tracking Working Group
Global HIV Prevention R&D Investment 2012 & 2013 (US$ millions) Funding Source Amount 2013 Amount 2012 % Change from 2012 US Public-Sector 887 925 -4% European Public- Sector Other Governments 77 86 -10% 65 69 -6% Philanthropic 193 203 -5% Industry 37 34 +9% All HIV Prevention R&D 1.26 1.31 -4% HIV Vaccines & Microbicides Resource Tracking Working Group
2013 Investment and Year-Over-Year Change HIV Vaccines & Microbicides Resource Tracking Working Group
2013 International Development Funding $154M HIV Vaccines & Microbicides Resource Tracking Working Group
Global HIV Prevention R&D Investment 2013 by Prevention Option (US$ millions) 2, 0% 44, 3% 32, 3% 117, 9% 36, 3% 210, 17% 818, 65% Preventive HIV Vaccines Microbicides Pre-exposure Prophylaxis Treatment as Prevention Male circumcision Female Condom Prevention of vertical transmission HIV Vaccines & Microbicides Resource Tracking Working Group
Global HIV Prevention R&D Investment 2012 & 2013 (US$ millions) HIV Prevention Option Preventive HIV vaccines Amount 2013 Amount 2012 % Change from 2012 818 847 -3% Microbicides 210 245 -14% Pre-exposure Prophylaxis Treatment as Prevention 36 31 +16% 117 98 +19% Male circumcision 32 41.6 -23% Female condoms 2.2 2 +10% Prevention of vertical transmission All HIV Prevention R&D 44 43.8 +0.5% 1.26 1.31 -4% HIV Vaccines & Microbicides Resource Tracking Working Group
Advocacy, policy and funding trends The US public sector funds the majority of HIV prevention R&D. Philanthropic organizations increasingly fund vital parts of HIV prevention research. Industry funding stayed almost flat and shifted to later development stages. International development priorities are evolving. The enabling environment has a profound effect on where trials take place and whether they are able to happen. HIV Vaccines & Microbicides Resource Tracking Working Group
Acknowledgements Significant contributions from the Working Group organizations, AVAC, the International AIDS Vaccine Initiative (IAVI), and the Joint United Nations Programme on HIV/AIDS (UNAIDS) and Working Group members Kevin Fisher (AVAC), Reuben Granich (UNAIDS), Thomas Harmon (IAVI), Polly Harrison (AVAC) and Mitchell Warren (AVAC).
For the full report, including graphics and past reports, visit www.hivresourcetracking.org
